MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Biological: MEDI0639
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 58
- Registration Number
- NCT01577745
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
MEDI-557 Adult Dosing
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Drug: PlaceboDrug: MEDI-557
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2013-10-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 42
- Registration Number
- NCT01562938
- Locations
- 🇺🇸
Research Site, Miami, Florida, United States
Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01554800
- Locations
- 🇺🇸
Cardiovascular and Pulmonary Branch (CPB) of NIH, Bethesda, Maryland, United States
A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Biological: MEDI7814, 1 MG/KGOther: PlaceboBiological: MEDI7814, 10 MG/KGBiological: MEDI7814, 20 MG/KGBiological: MEDI7814, 3 MG/KG
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 125
- Registration Number
- NCT01544361
- Locations
- 🇺🇸
Research Site, Omaha, Nebraska, United States
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1
Completed
- Conditions
- Allergic AsthmaAtopic DermatitisAllergic RhinitisHealthy Volunteers
- Interventions
- Biological: MEDI4212 15 mg SubcutaneousBiological: MEDI4212 150 mg SubcutaneousBiological: MEDI4212 300 mg SubcutaneousBiological: MEDI4212 300 mg IntravenousOther: PlaceboBiological: OmalizumabBiological: MEDI4212 5 mg SubcutaneousBiological: MEDI4212 60 mg Subcutaneous
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 295
- Registration Number
- NCT01544348
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
Phase 1
Completed
- Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
- Interventions
- Drug: MEDI-573 (1 of 3 doses)
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 6
- Registration Number
- NCT01498952
- Locations
- 🇺🇸
Research Site, Las Vegas, Nevada, United States
Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)
Phase 1
Terminated
- Conditions
- RSV Infection
- Interventions
- Drug: MEDI-557Drug: Placebo
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 7
- Registration Number
- NCT01475305
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2
Completed
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 183
- Registration Number
- NCT01466153
- Locations
- 🇵🇱
Research Site, Warszawa, Poland
An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF
Completed
- Conditions
- Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 476
- Registration Number
- NCT01455402
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2
Completed
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Drug: MEDI-551 2 mg/kgDrug: ICEProcedure: Autologous Stem Cell Transplant (ASCT)Drug: MEDI-551 4 mg/kg
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 187
- Registration Number
- NCT01453205
- Locations
- 🇹🇷
Research Site, Talas, Turkey
© Copyright 2025. All Rights Reserved by MedPath